

Report on 2021 Lobbying Activities

The Board believes that it is in the best interest of our shareholders for McKesson to be an effective participant in the public policy process. The Board exercises oversight of McKesson's political and public policy activities. The Senior Vice President of Public Affairs has management responsibility for all political contributions, lobbying activities and related expenditures and consults with McKesson's senior business leaders and internal and external counsel to help ensure alignment between McKesson's political engagement activities, McKesson's public policy priorities and applicable law. The Senior Vice President of Public Affairs provides regular updates to the Board on such matters consisting of reports on public policy issues, political engagements, lobbying activities and corporate political contributions.

We disclose to our shareholders on an annual basis the aggregate dollars McKesson spends on lobbying activities and its policy priorities and material lobbying efforts in the year, including with respect to laws or regulations governing the distribution of controlled substances. The information below pertains to McKesson's lobbying activities during the calendar year ended December 31, 2021 (CY21).

Public Policy Priorities for Lobbying in CY21:

- Access to affordable medicines: McKesson advocates for stronger community providers, new payment models and healthcare technology and data insights which can go a long way to making sure people can access and afford the treatments they need.
- Connecting the healthcare landscape: McKesson is a member of the Healthcare Innovation Alliance, which works to harness the power of data and technology to improve patient care and speed up the development of potentially life-saving treatments.
- Promoting community healthcare providers: In the U.S., a shortage of primary care providers and an aging population means quality healthcare can be difficult to access in some areas. McKesson is a member of the Future of Pharmacy Care Coalition, ensuring patient access to essential care and services by pharmacists.
- Addressing healthcare disparities: McKesson believes that health equity belongs to every patient. Historical and present day disparities and inequities impacting patient access, quality of care and outcomes must end.
- Protecting drug supply-chain security: McKesson is the centralized distributor for COVID-19 vaccines and ancillary supply kits. McKesson supports public-private partnership of the strategic national stockpile and warm rotational managed inventory of essential medicines and medical products necessary for federal, state, and local emergency preparedness and response efforts.
- Advancing a comprehensive oncology healthcare ecosystem: McKesson has the largest network of independent community oncologists, supporting value-based care and better patient outcomes. We generate real-world data and evidence that accelerate oncology innovation, make clinical trials more accessible, deliver specialty therapy, conduct research, and help patients access and afford medicines. McKesson supports expanding clinical trial eligibility to increase patient diversity and removing barriers that prevent clinical trial completion.
- Recommending ways to address the opioid crisis: McKesson believes the opioid epidemic must be addressed through a comprehensive approach that includes doctors, pharmacists, distributors, manufacturers, payers, regulators and law enforcement. McKesson's opioid public

policy recommendations focus on the need for public and private partnerships that promote patient-centered solutions and foster clinical collaboration across the care continuum.

Topics for Material Federal and State Lobbying Efforts in CY21

Clinical Trial Patient Eligibility and Diversity
Data Privacy
Drug Pricing
Direct and Indirect Remuneration (DIR) Fees
Emergency Preparedness and Response
Healthcare Benefit and Pricing Transparency
Healthcare Equity and Racial Disparities
*Medical Supply and Medicine Distribution Licensure
Pharmacist Payment, Recognition, and Reimbursement
*Taxes
Prescription Safety Alert System (RxSAS)

* CY21 material lobbying efforts with respect to laws or regulations governing the distribution of controlled substances: Our Public Affairs team engaged with state elected officials on legislation regarding licensing and controlled substance reporting requirements for drug distributors. While specifics vary by state, legislation may require manufacturers and wholesalers to prepare a complete record of all shipments of controlled substances and provide the report to a state agency. In addition, our Public Affairs team engaged with state elected officials on fees related to the distribution of controlled substances. Legislation typically fits within the following categories, with tax/fee legislative proposals varying from state-to-state: gross receipts/revenue tax, tax, licensure fees, and controlled substance registration fees. Finally, our Public Affairs team engaged elected officials in support of legislation to establish a national prescription safety alert system. A prescription safety alert system would utilize patient prescription history to identify patients at risk for opioid abuse. The system would provide proactive, real-time clinical alerts, integrated into pharmacists' and potentially prescribers' workflow, across state lines.

Lobbying Spend

In CY21, McKesson spent approximately \$425,000 and \$1,235,000 on external federal and state lobbyist expenses, respectively:

Federal

Name of Firm	Payment Range
Todd Strategy	\$100,001 - \$200,000
Akin Gump	\$100,001 - \$200,000
Venn Strategies	\$25,001 – \$50,000

State

Name of Firm	State	Payment Range
Aprea & Micheli	California	\$100,001-\$200,000
Capital Focus	Colorado	\$50,001-\$100,000
Bivens & Associates	Tennessee	\$50,001-\$100,000
Faegre	Minnesota	\$25,001-\$50,000
HillCo Partners	Texas	\$100,001-\$200,000
Impact Management	Arkansas	Less than or equal to \$25,000
Komjath & Kean	New Jersey	\$25,001-\$50,000
McGuire Woods	Virginia	\$50,001-\$100,000
O'Neill & Associates	Massachusetts	\$50,001-\$100,000
Southern Group of Florida	Florida	\$50,001-\$100,000
The Success Group	Ohio	\$50,001-\$100,000
Strategic Partnership Alliance	Illinois	\$50,001-\$100,000
The JL Morgan	Georgia	\$50,001-\$100,000
Triadvocates	Arizona	\$50,001-\$100,000
Rotunda Group	Kentucky	\$50,001-\$100,000
Oxley & Associates	Oregon	\$50,001-\$100,000
Troutman Sanders	Virginia	\$25,001-\$50,000
Smith, Anderson, Blout	North Carolina	Less than or equal to \$25,000
Capitol Plus	Oklahoma	\$25,001-\$50,000
TT&B Government Affairs	South Carolina	\$50,001-\$100,000
Michigan Legislative Consultants	Michigan	\$25,001-\$50,000

McKesson requests information regarding annual lobbying spend from health policy, 501(c)(4) and/or trade organizations where we are members and to which our annual payments exceeded \$25,000. For 2021, the aggregate dollars reportedly spent on lobbying activities from the dues we paid each of those organizations included those listed on Attachment A.

We are a member of and make payments to certain health policy, 501(c)(4) and/or trade organizations because they draft and support model legislation for purposes of advancing healthcare issues consistent with our public policy priorities. In 2021, those organizations and the amounts spent were:

Name of Organization	Amount Reported
National Association of Chain Drug Stores	\$800,000.00
National Community Pharmacists Association	\$200,000.00
American Disease Prevention Coalition	\$25,000.00
National Association of State Pharmacy Associations	\$25,000.00

For more information regarding McKesson's political activities, including a copy of our Political Engagement and Lobbying Policy, please visit <https://www.mckesson.com/About-McKesson/Public-Affairs/Political-Engagement/>.

###

Attachment A

Name of Organization	Amount
Healthcare Distribution Alliance	\$4,800,000.00
Healthcare Information and Management Systems Society, Inc.	\$30,000.00
National Association of Chain Drug Stores (NACDS)	\$679,999.92
National Association of Community Health Centers	\$85,000.00
Senior Care Pharmacy Coalition	\$50,000.00
National Community Pharmacist Association	\$200,000.00
NCPA Legislative/Legal Defense Fund	\$50,000.00
Oncology Community Oncology Alliance	\$180,000.00
Health Industry Distributors Association	\$120,761.00
Healthcare Leadership Council	\$200,000.00
American Disease Prevention Coalition	\$50,000.00
Health Innovation Alliance	\$50,000.00
American Pharmacies Services Corp.	\$60,000.00
California Chronic Care Coalition	\$40,000.00
State Privacy and Security Coalition	\$50,000.00
Future of Pharmacy Care Coalition	\$250,000.00
Indian Pharmacists Association of CA	\$25,000.00
Iowa Pharmacy Association	\$30,000.00
WA State Pharmacy Association	\$50,000.00
Florida Health Care Association	\$30,500.00
American Pharmacy Services Corporation Foundation	\$60,000.00
American Pharmacy Cooperative Inc.	\$35,000.00
DSCSA Governance Committee	\$50,000.00

HDA Research Foundation	\$100,000.00
IPC - Independent Pharmacy Cooperative Annual Conference	\$26,000.00
KLAS Research Membership	\$50,500.00
National Association of Chain Drug Stores Foundation Reception/Dinner Sponsorship	\$30,000.00
National Association of Chain Drug Stores	\$65,500.00
National Council for Prescription Drug Programs	\$75,000.00
NCPA Annual Convention and Trade Exposition	\$50,000.00
NCPA Foundation Presidential Scholarship	\$50,000.00
NCPA Ownership Workshop	\$200,000.00
One Columbus	\$25,000.00
Oncology Nursing Society Bridge Sponsorship	\$35,000.00
Pharmacy Quality Alliance	\$35,405.00
The Leukemia & Lymphoma Society Inc/2021 Light the Night	\$100,000.00
Urgent Care Association	\$25,000.00